IMV Welcomes Marc Jasmin as Senior Director, Investor Relations and Communications
December 05 2018 - 7:05AM
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology
corporation, today announced that Marc Jasmin has joined the
Company in the newly created role of Senior Director,
Investor Relations and Communications.
For the last 15 years, Mr. Jasmin has served in
a broad range of investor and communications-focused positions. His
experience includes overseeing the investor relations department of
Cascades (CAS/TSX) and serving as Director, Investor Relations, of
Boralex (BLX/TSX), the latter of which has a market cap over $1.5B
CAD and is a leader in Canada and France in the renewable energy
space. Under his leadership, both Cascades and Boralex were
nominated as best overall investor relations, or investor relations
officer, in applicable categories. Prior to these positions, Mr.
Jasmin spent seven years in various financial and investor-focused
roles, ranging from financial advisor for a large Canadian
brokerage firm to an institutional salesperson.
Pierre Labbé, Chief Financial Officer at IMV,
stated, “Marc’s deep understanding of the financial markets, strong
interpersonal skills, and successful track record in investor
relations will be key as we continue to raise awareness about IMV
within the financial community. The leadership team at IMV is
looking forward to working with Marc to continue to create and
sustain long-term shareholder value and, ultimately, better options
for patients and clinicians who remain underserved in today’s
cancer treatment landscape.”
Mr. Jasmin earned his BAA and Certificate of
Accounting from the University of Montreal. He is a member of the
Quebec Order of Chartered Professional Accountants (CPA, CMA).
About IMV
IMV Inc., formerly Immunovaccine Inc.,
is a clinical stage biopharmaceutical company dedicated to making
immunotherapy more effective, more broadly applicable, and more
widely available to people facing cancer and other serious
diseases. IMV is pioneering a new class of immunotherapies based on
the Company’s proprietary drug delivery platform. This patented
technology leverages a novel mechanism of action that enables the
programming of immune cells in vivo, which are aimed at
generating powerful new synthetic therapeutic capabilities. IMV’s
lead candidate, DPX-Survivac, is a T cell-activating immunotherapy
that combines the utility of the platform with a target: survivin.
IMV is currently assessing DPX-Survivac as a combination therapy in
multiple clinical studies with Incyte and Merck. Connect
at www.imv-inc.com
IMV Forward-Looking
Statements
This press release contains forward-looking
information under applicable securities law. All information that
addresses activities or developments that we expect to occur in the
future is forward-looking information. Forward-looking statements
are based on the estimates and opinions of management on the date
the statements are made. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the Corporation, including access to
capital, the successful completion of clinical trials and receipt
of all regulatory approvals. IMV Inc. assumes no
responsibility to update forward-looking statements in this press
release except as required by law. These forward-looking statements
involve known and unknown risks and uncertainties and those risks
and uncertainties include, but are not limited to, our ability to
access capital, the successful and timely completion of clinical
trials, the receipt of all regulatory approvals and other risks
detailed from time to time in our ongoing quarterly filings and
annual information form Investors are cautioned not to rely on
these forward-looking statements and are encouraged to read IMV’s
continuous disclosure documents, including its current annual
information form, as well as its audited annual consolidated
financial statements which are available on SEDAR
at www.sedar.com and on EDGAR
at www.sec.gov/edgar.
Contacts for IMV:
MEDIA Mike Beyer, Sam Brown
Inc.T: (312) 961-2502 E: mikebeyer@sambrown.com
INVESTOR RELATIONSMarc Jasmin, CPA,
CMA, Senior Director, Investor Relations and
CommunicationsT: (902) 492-1819 M:(514) 617-8481 E:
mjasmin@imv-inc.com
Patti Bank, Managing Director, Westwicke
PartnersO: (415) 513-1284T: (415) 515-4572 E:
patti.bank@westwicke.com
IMV (TSX:IMV)
Historical Stock Chart
From Aug 2024 to Sep 2024
IMV (TSX:IMV)
Historical Stock Chart
From Sep 2023 to Sep 2024